UK clinical trials - updated daily from ClinicalTrials.gov
Find clinical trials for prostate cancer in the United Kingdom. Explore treatment pathways from localised to metastatic disease.
Prostate cancer is the most common cancer in men in the UK, with ~52,000 new cases yearly. Many prostate cancers grow slowly and may not need immediate treatment (active surveillance). However, aggressive or metastatic prostate cancer requires systemic treatment. Outcomes have improved dramatically with newer hormonal therapies and targeted treatments.
When prostate cancer spreads (metastatic), treatment aims to control the cancer and maintain quality of life. First-line for metastatic hormone-sensitive prostate cancer (mHSPC) combines hormone therapy (ADT) with newer agents like abiraterone, enzalutamide, or apalutamide. When the cancer becomes resistant (mCRPC), options include further hormonal therapy, chemotherapy (docetaxel, cabazitaxel), PARP inhibitors (olaparib, rucaparib for BRCA mutations), and radiopharmaceuticals (radium-223, lutetium-PSMA).
PSMA (prostate-specific membrane antigen) targeted therapy is a major advance. Lutetium-177 PSMA (Pluvicto) delivers radiation directly to prostate cancer cells. Available through clinical trials and approved by NICE for mCRPC after other treatments. This precision approach significantly reduces side effects compared to traditional chemotherapy.
Active trial areas include: PSMA-targeted therapies (radioligand and CAR-T), new PARP inhibitor combinations, bispecific antibodies, cancer vaccines (PROSTVAC), and combinations of immunotherapy with hormonal therapy. The UK's Prostate Cancer UK charity funds significant research and maintains a trial finder.
Free AI-powered matching - no signup required
Search prostate carcinoma Trials →